NCT05457010 2024-06-12
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Phase 1 Unknown
Clinical Trials
152 trialsNCT04021368 2024-02-14
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA
Phase 1 Unknown
NCT05641259 2024-02-02
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Unknown
NCT04358393 2024-02-01
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06234904 2024-01-31
Study of IBR733 Cell Injection in Acute Myeloid Leukemia
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1 Unknown
NCT06209671 2024-01-17
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT04284228 2024-01-16
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
NexImmune Inc.
Phase 1/2 Unknown
NCT03614858 2023-11-29
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT03896854 2023-11-29
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT04964518 2023-10-25
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT05716919 2023-10-23
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Machaon Biotherapeutics, Inc.
Phase 1 Unknown
NCT04825496 2023-09-21
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT03709914 2023-09-15
Pediatric_PK
Nabriva Therapeutics AG
Phase 1 Unknown
NCT06008405 2023-09-06
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03867682 2023-08-04
Venetoclax and Lintuzumab-Ac225 in AML Patients
Actinium Pharmaceuticals
Phase 1/2 Unknown
NCT05970822 2023-08-01
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT05226468 2023-07-27
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
New Epsilon Innovation Limited
Phase 1 Unknown
NCT05690425 2023-07-24
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT02825836 2023-07-13
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Telios Pharma, Inc.
Phase 1/2 Unknown
NCT04763083 2023-07-07
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NovalGen Ltd.
Phase 1 Unknown
NCT04578613 2023-06-05
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT05471323 2023-05-19
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
Guangdong Ruishun Biotech Co., Ltd
Phase 1 Unknown
NCT04471064 2023-05-18
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase 1 Unknown
NCT05487651 2023-05-18
ANCHOR2
Athenex, Inc.
Phase 1 Unknown
NCT04265963 2023-04-18
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04272125 2023-04-18
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04648475 2023-04-18
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04649983 2023-04-18
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT05503355 2023-04-04
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
BioSight Ltd.
Phase 1/2 Unknown
NCT03883087 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT03883100 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT05448599 2023-03-15
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT04749355 2023-03-09
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
BioSight Ltd.
Phase 2 Unknown
NCT04669067 2023-02-17
TL-895 and KRT-232 Study in Acute Myeloid Leukemia
Telios Pharma, Inc.
Phase 1/2 Unknown
NCT05731219 2023-02-16
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT05727683 2023-02-14
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Unknown
NCT05722171 2023-02-10
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03709017 2022-12-07
Iclusig PMS in CML or Ph+ALL Patients
Korea Otsuka Pharmaceutical Co., Ltd.
Unknown
NCT04100187 2022-12-01
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Kecellitics Biotech Company Ltd
Phase 1 Unknown
NCT05291390 2022-11-29
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Armaceutica, Inc.
Phase 2 Unknown
NCT05619861 2022-11-17
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT05610202 2022-11-09
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05227898 2022-10-25
RESTORE
Blue Note Therapeutics
Phase NA Unknown
NCT05489276 2022-08-05
Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04502394 2022-08-04
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Kartos Therapeutics, Inc.
Phase 1/2 Unknown
NCT05480501 2022-07-29
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05212584 2022-07-06
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Phase 1 Unknown
NCT05445765 2022-07-06
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Phase 1 Unknown